Multicenter quality control of hepatitis C virus protease inhibitor resistance genotyping.

doi:10.1128/JCM.03032-12

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Multicenter quality control of hepatitis C virus protease inhibitor resistance genotyping.

Journal of clinical microbiology - 1 May 2013

Vallet Sophie, Larrat Sylvie, Laperche Syria, Le Guillou-Guillemette Hélène, Legrand-Abravanel Florence, Bouchardeau Françoise, Pivert Adeline, Henquell Cécile, Mirand Audrey, André-Garnier Elisabeth, Giordanengo Valérie, Lagathu Gisèle, Thibault Vincent, Scholtes Caroline, Schvoerer Evelyne, Gaudy-Graffin Catherine, Maylin Sarah, Trimoulet Pascale, Brochot Etienne, Hantz Sébastien, Gozlan Joël, Roque-Afonso Anne-Marie, Soussan Patrick, Plantier Jean-Christophe, Charpentier Charlotte, Chevaliez Stéphane, Colson Philippe, Mackiewicz Vincent, Aguilera Lina, Rosec Sylvain, Gouriou Stéphanie, Magnat Nelly, Lunel-Fabiani Françoise, Izopet Jacques, Morand Patrice, Payan Christopher, Pawlotsky Jean-Michel

Abstract excerpt

Hepatitis C virus (HCV) protease inhibitor resistance-associated substitutions are selected during triple-therapy breakthrough. This multicenter quality control study evaluated the expertise of 23 French laboratories in HCV protease inhibitor resistance genotyping. A panel of 12 well-defined blinded samples comprising two wild-type HCV strains, nine transcripts from synthetic NS3 mutant samples or from clinical...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Amino Acid Sequence

Share to Antiviral Agents

Share to Drug Resistance, Viral

Share to Hepacivirus

Share to Protease Inhibitors

Share to Quality Control

Share to Sequence Analysis, DNA

Share to Viral Nonstructural Proteins

Source

Open in PubMed Open full text

Identifiers

PMID: 23426922
DOI: 10.1128/JCM.03032-12
PMCID: PMC3647889

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Multicenter quality control of hepatitis C virus protease inhibitor resistance genotyping.PMID 23426922Read ↗

Nationwide experience of treatment with protease inhibitors in chronic hepatitis C patients in Denmark: identification of viral resistance mutations.Semantic proximity Read ↗

Virologic Tools for HCV Drug Resistance TestingSemantic proximity Read ↗

Protease inhibitor resistance mutations in untreated Brazilian patients infected with HCV: novel insights about targeted genotyping approaches.Semantic proximity Read ↗

Resistance mutations are rare among protease inhibitor treatment-naive hepatitis C genotype-1 patients with or without HIV coinfection.Semantic proximity Read ↗

Hepatitis C virus resistance to protease inhibitors.Semantic proximity Read ↗

Diversity of 1,213 hepatitis C virus NS3 protease sequences from a clinical virology laboratory database in Marseille university hospitals, southeastern France.Semantic proximity Read ↗

Underestimation of HIV type 1 drug resistance mutations: results from the ENVA-2 genotyping proficiency program.Semantic proximity Read ↗

The effect of the first-generation HCV-protease inhibitors boceprevir and telaprevir and the relation to baseline NS3 resistance mutations in genotype 1: experience from a small Swedish cohort.Semantic proximity Read ↗

Prevalence of hepatitis C virus mutants resistant to protease inhibitors among Polish HCV genotype 1-infected patients.Semantic proximity Read ↗

Hepatitis C virus NS3 protease genotyping and drug concentration determination during triple therapy with telaprevir or boceprevir for chronic infection with genotype 1 viruses, southeastern France.Semantic proximity Read ↗

HCV NS3 sequencing as a reliable and clinically useful tool for the assessment of genotype and resistance mutations for clinical samples with different HCV-RNA levels.Semantic proximity Read ↗

Characterization of naturally occurring protease inhibitor-resistance mutations in genotype 1b hepatitis C virus patientsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.